“Right to try” legislation and the management of prostate cancer

As many of our readers may be aware, the “right to try” treatments using investigational new drugs outside of the clinical trials processes required by drug developers and overseen by the US Food and Drug Administration is a current “hot topic” on Capitol Hill. … READ MORE …

The language of denial of access to high-quality prostate cancer care today

If you look at the corporate web site for eviCore Healthcare, the company describes itself as follows: … READ MORE …

Of mice and men all over again …

Yet another set of researchers have found yet another possible new drug that seems to have significant activity in management of prostate cancer — in mice! Whether it will have activity in men is a whole other question. … READ MORE …

Modified poliovirus in treatment of metastatic prostate cancer?

Earlier this year (on March 29 to be precise) some of our readers may remember seeing a two-part 60 Minutes program about the use of a modified form of poliovirus in the successful treatment of some patients with deadly forms of brain cancer. … READ MORE …

Potential future agents in the management of mCRPC

A new article by Antonarakis and Armstrong in full text on the Medscape web site reviews available information on a wide range of currently investigational agents for the treatment of metastatic, castration-resistant prostate cancer (mCRPC), including … READ MORE …